Back to top

Analyst Blog

Endocyte, Inc. (ECYT - Snapshot Report) reported first quarter 2013 net loss per share of 11 cents, wider than the Zacks Consensus Estimate of a loss of 5 cents but narrower than  the year-ago loss of 27 cents.

First quarter 2013 revenues were $14.5 million compared with no revenues in the first quarter 2012. Revenues comprised solely of collaboration revenues. Revenues surpassed the Zacks Consensus Estimate of $14 million.

In the reported quarter, research and development expenses were $12.3 million, up 92.2%. The company’s effort to develop its pipeline was primarily responsible for the increase. In the reported quarter, general and administrative (G&A) expenses jumped 103.2% to $6.3 million. The increase was attributable to establishing commercial capability. An increase in compensation expenses was also responsible for pushing G&A costs up.

In 2012, Endocyte submitted a marketing authorization application (MAA) seeking approval for vintafolide for platinum-resistant ovarian cancer. The company is also seeking EU approval for a folate-targeted molecular imaging agent, etarfolatide. Both were granted orphan drug status in the EU in 2012. The company expects a decision from the European Commission on both candidates in the fourth quarter of 2013.

Endocyte and its partner Merck & Co. Inc. (MRK - Analyst Report) will initiate a phase II randomized trial on vintafolide in folate receptor-positive triple negative breast cancer in the fourth quarter of 2013.

For its folate-targeted tubulysin therapeutic, Endocyte will file an investigational new drug (IND) application and initiate a study in the third quarter of 2013.

Endocyte maintained its cash, cash equivalents and investments guidance in the range of $145 - $160 million as on Dec 31, 2013.

Endocyte carries a Zacks Rank #4 (Sell). Currently, companies like Lannett Company, Inc. (LCI - Snapshot Report) and Catalyst Pharmaceutical Partners Inc. (CPRX - Snapshot Report)  look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
QIHOO 360 T… QIHU 95.04 +4.95%
PILGRIM'S P… PPC 31.52 +3.72%
CLAYTON WIL… CWEI 138.97 +3.55%
FLAMEL TECH… FLML 14.02 +3.16%
CALLON PETE… CPE 11.50 +3.14%